Recent Quotes (30 days)

You have no recent quotes
chg | %

iCo Therapeutics Inc  

(Public, CVE:ICO)   Watch this stock  
Find more results for TSE:ICO
0.0800
Apr 24 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.03 - 0.38
Open     -
Vol / Avg. 0.00/1.87M
Mkt cap 6.76M
P/E     -
Div/yield     -
EPS -0.05
Shares 84.46M
Beta 0.11
Inst. own     -
May 27, 2015
Q1 2015 iCo Therapeutics Inc Earnings Release (Estimated) Add to calendar
Apr 15, 2015
Q4 2014 iCo Therapeutics Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -13.40% -163.29%
Return on average equity -18.77% -338.57%
Employees 5 -
CDP Score - -

Address

760-777 Hornby Street
VANCOUVER, BC V6Z 1S4
Canada
+1-604-6029414 (Phone)
+1-604-6029699 (Fax)

Website links

Description

iCo Therapeutics Inc. is a Canada-based development stage pharmaceutical company. The Company is focused on the reprofiling and repositioning of drugs and drug candidates with a previous clinical history for new disease indications. iCo acquires candidates with identified targets and demonstrations of systemic safety, including reformulations of off‐patent drugs. The Company is developing iCo-007, a second generation antisense inhibitor targeting C-raf kinase messenger ribonucleic acid (mRNA), for the treatment of retinal neovascular diseases such as diabetic retinopathy (including diabetic macular edema). The iCo-008 (also known as Bertilimumab or CAT-213) is a human immunoglobulin monoclonal antibody targeting eotaxin-1, a member of the chemokine family of proteins that acts as messenger molecules between the cells of the immune system. The Company owns the exclusive rights to an oral Amphotericin B delivery system for life-threatening infections.

Officers and directors

William W. Jarosz J.D. Independent Chairman of the Board
Andrew J Rae President, Chief Executive Officer, Director
W. John Meekison Chief Financial Officer, Corporate Secretary
Peter Hnik M.D. Chief Medical Officer
Age: 51
Richard W. Barker OBE Independent Director
Age: 65
Noel F. Hall Independent Director
Age: 45
Douglas G. Janzen Independent Director
Age: 41